Budesonide

Generic Name
Budesonide
Brand Names
Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
Drug Type
Small Molecule
Chemical Formula
C25H34O6
CAS Number
51333-22-3
Unique Ingredient Identifier
Q3OKS62Q6X
Background

Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.

Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.

Indication

Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. E...

Associated Conditions
Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

Pulmicort Respules on Relapse Rates After Treatment in the ED

Phase 4
Withdrawn
Conditions
Asthma
Interventions
Drug: pulmicort respules
First Posted Date
2008-01-02
Last Posted Date
2011-09-05
Lead Sponsor
Phoenix Children's Hospital
Registration Number
NCT00584636
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome

Phase 4
Completed
Conditions
Obstructive Sleep Apnea
Interventions
Drug: placebo
Drug: Budesonide
First Posted Date
2007-11-19
Last Posted Date
2017-07-11
Lead Sponsor
University of Louisville
Target Recruit Count
62
Registration Number
NCT00560586
Locations
🇺🇸

Kosair Children's Hospital Sleep Center, Louisville, Kentucky, United States

Symbicort Rapihaler Therapeutic Equivalence Study

First Posted Date
2007-09-28
Last Posted Date
2012-08-15
Lead Sponsor
AstraZeneca
Target Recruit Count
742
Registration Number
NCT00536731
Locations
🇵🇱

Research Site, Wroclaw, Poland

Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Budesonide
Drug: Conventional Asthma Therapy
First Posted Date
2007-07-31
Last Posted Date
2012-08-27
Lead Sponsor
AstraZeneca
Target Recruit Count
241
Registration Number
NCT00509028
Locations
🇯🇵

Research Site, Takizawa, Iwate, Japan

Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma

Phase 3
Completed
Conditions
Asthma
First Posted Date
2007-07-19
Last Posted Date
2011-08-24
Lead Sponsor
AstraZeneca
Target Recruit Count
240
Registration Number
NCT00504062
Locations
🇯🇵

Research Site, Takizawa, Iwate, Japan

Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma

Phase 4
Completed
Conditions
Asthma
First Posted Date
2007-06-22
Last Posted Date
2007-06-28
Lead Sponsor
Medical University of Lodz
Target Recruit Count
150
Registration Number
NCT00490243
Locations
🇵🇱

Department of Pediatrics and Allergy, Medical University of Lodz, Poland, Lodz, Poland

Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma

First Posted Date
2007-06-19
Last Posted Date
2010-04-13
Lead Sponsor
Medical University of Lodz
Target Recruit Count
96
Registration Number
NCT00487773
Locations
🇵🇱

Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland

Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients

Phase 2
Completed
Conditions
Copd Bronchitis
Interventions
Drug: TPI 1020
Drug: Budesonide
Drug: Placebo
First Posted Date
2007-06-07
Last Posted Date
2012-12-03
Lead Sponsor
Syntara
Target Recruit Count
62
Registration Number
NCT00483743
Locations
🇨🇦

CHUS -Hopital FLEURIMONT, Sherbrooke, Quebec, Canada

🇨🇦

Clinique Medical Les Saules, Les Saules, Quebec, Canada

🇨🇦

Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada

and more 10 locations

Comparison of Combination Therapy: Montelukast and Inhaled Steroid on Exercise Induced Bronchoconstriction

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: budesonide
Other: placebo
Drug: montelukast
First Posted Date
2007-04-19
Last Posted Date
2009-10-21
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
18
Registration Number
NCT00462592
Locations
🇨🇦

Hospital for Sick Children, Toronto, Ontario, Canada

🇨🇦

Hamilton Health Sciences-McMaster University, Hamilton, Ontario, Canada

Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis

First Posted Date
2007-03-21
Last Posted Date
2014-05-19
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
92
Registration Number
NCT00450086
Locations
🇩🇪

Center of digestive diseases, Hamburg, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy